Aclaris Therapeutics (ACRS) Stock Price, Financials & Analysis

Key Stats

Market Cap638.89 Mn

P/E-8.02

FCF (Yr)-47.22 Mn

ROA (Yr)-36.10

EV to EBIT-2.62

Net Income (Yr)-64.92 Mn

Enterprise Value236.88 Mn

Add ratio to table…

About

Aclaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno inflammatory diseases. The company leverages its proprietary KINect drug discovery platform and an integrated approach to identify candidates with high target affinity, specificity and potency. Its pipeline includes monoclonal antibodies, bispecific antibodies and covalent small molecule inhibitors…

Aclaris Therapeutics generates revenue primarily through upfront licensing fees, milestone payments and royalties from collaborations with third-party partners. The company has entered into exclusive license agreements for its product candidates, such as the agreement with Biosion for bosakitug and ATI-052, which provide potential future payments contingent on development, regulatory and sales milestones. No commercial product sales are currently reported as all candidates remain in clinical development.

Aclaris Therapeutics, Inc. occupies an early stage position in the competitive biopharmaceutical landscape focused on immuno inflammatory therapies. It faces competition from large pharmaceutical companies such as Amgen, AstraZeneca, GlaxoSmithKline and Pfizer which market approved biologics and small molecule agents targeting similar pathways. The company's competitive advantages stem from its proprietary KINect platform enabling discovery of difficult to drug kinases and its pipeline of differentiated molecules such as the high affinity TSLP antibody bosakitug and the bispecific antibody ATI-052. These assets aim to address unmet medical needs where existing therapies show limitations in efficacy or safety.

Aclaris Therapeutics, Inc. collaborates with biotechnology and pharmaceutical partners to advance its product candidates, exemplified by its exclusive licensing agreement with Biosion for bosakitug and ATI-052 and its arrangement with CTTQ for development in Greater China. The company does not currently sell products directly to patients or healthcare providers, so its customer base consists of corporate partners and potential future licensees. These collaborations provide the resources needed for clinical development, regulatory approval and eventual commercialization.

How Aclaris Therapeutics ranks

Ranked against the 671 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −6.77xMedian 17.8x 62^nd
P/FCFNegative free cash flow −7.23xMedian 21.0x 58^th
P/Operating cash flowNegative operating cash flow −7.24xMedian 16.8x 57^th
P/S 85.1xMedian 8.14x 17^th
P/B 3.26xMedian 2.02x 35^th
P/Tangible book 3.26xMedian 2.24x 38^th
EV/EBITDANegative EBITDA −4.77xMedian 15.7x 51^st
EV/EBITNegative EBIT −4.75xMedian 20.9x 53^rd
EV/Revenue 67.2xMedian 5.92x 16^th
EV/FCFNegative free cash flow −5.71xMedian 22.0x 49^th
EV/Operating cash flowNegative operating cash flow −5.72xMedian 18.3x 49^th
PEG (3Y EPS CAGR)Negative earnings −0.22Median 0.36 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −59.3%Median 11.0% 13^th
Revenue CAGR (3Y) −33.2%Median 10.4% 14^th
Gross profit growth (1Y) −62.4%Median 11.8% 11^th
Gross profit CAGR (3Y) −34.3%Median 12.3% 8^th
Operating income growth (1Y) 41.0%Median −1.6% 81^st
Operating income CAGR (3Y) 9.6%Median 1.4% 61^st
Net income growth (1Y) 43.8%Median −3.3% 80^th
Net income CAGR (3Y) 11.4%Median −0.1% 63^rd
EPS growth (1Y) 53.9%Median 22.4% 70^th
EPS CAGR (3Y) 31.0%Median 25.9% 58^th
Operating cash flow growth (1Y) −75.2%Median −0.4% 14^th
Operating cash flow CAGR (3Y) 6.0%Median 2.1% 57^th
Free cash flow growth (1Y) −75.1%Median −0.1% 15^th
Free cash flow CAGR (3Y) 6.3%Median 2.5% 55^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 79.2%Median 74.2% 55^th
EBITDA margin −1,408%Median −214% 28^th
Operating margin −1,414%Median −213% 27^th
Pretax margin −1,308%Median −205% 28^th
Net margin −1,244%Median −196% 29^th
FCF margin −1,177%Median −181% 25^th
Operating cash flow margin −1,175%Median −175% 25^th
Return on equity −57.5%Median −54.7% 48^th
Return on assets −42.3%Median −41.1% 49^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −52.1%Median −47.8% 47^th
Asset turnover 0.03xMedian 0.18x 26^th
Cash conversion (OCF / net income)Net income is not positive 0.94xMedian 1.14x Not meaningful —
Stock comp / revenue 185%Median 29.2% 27^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.27x No data —
Net debt / EBITDA —Median 1.22x No data —
Debt / FCF —Median 3.65x No data —
Liabilities / assets 22.8%Median 32.3% 63^rd
Equity / assets 77.2%Median 67.7% 63^rd
Interest coverage —Median −10.0x No data —
Current ratio 5.09xMedian 4.37x 55^th
Quick ratio 4.72xMedian 3.65x 58^th
Cash ratio 4.72xMedian 3.35x 59^th
Altman Z-score −0.84Median −0.80 50^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,264.65 Bn	45.85	14.63	49.50 Bn
2	JNJ	Johnson & Johnson	677.74 Bn	42.11	6.82	44.65 Bn
3	ABBV	AbbVie Inc.	517.10 Bn	50.00	7.83	80.90 Bn
4	MRK	Merck & Co., Inc.	362.23 Bn	147.67	5.38	53.78 Bn
5	NVS	Novartis Ag	315.90 Bn	24.55	6.03	9.59 Bn
6	AZN	Astrazeneca Plc	289.40 Bn	33.26	5.34	32.35 Bn
7	AMGN	Amgen Inc	249.90 Bn	26.61	6.42	54.01 Bn
8	ACRS	Aclaris Therapeutics, Inc.	0.64 Bn	-8.02	99.81	-

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,264.65 Bn

45.85

14.63

49.50 Bn

JNJ

Johnson & Johnson

677.74 Bn

42.11

6.82

44.65 Bn

ABBV

AbbVie Inc.

517.10 Bn

50.00

7.83

80.90 Bn

MRK

Merck & Co., Inc.

362.23 Bn

147.67

5.38

53.78 Bn

NVS

Novartis Ag

315.90 Bn

24.55

6.03

9.59 Bn

AZN

Astrazeneca Plc

289.40 Bn

33.26

5.34

32.35 Bn

AMGN

Amgen Inc

249.90 Bn

26.61

6.42

54.01 Bn

ACRS

Aclaris Therapeutics, Inc.

0.64 Bn

-8.02

99.81

Aclaris Therapeutics ACRS

About

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

How Aclaris Therapeutics ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Aclaris Therapeutics ACRS

About

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

How Aclaris Therapeutics ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password